

ClinGen Long QT Syndrome Gene Curation Expert Panel

Date	Your Name	Do you work for a laboratory that offers fee-for-service testing related to the work of your Expert Panel?	Have you made substantial contributions to the literature implicating a gene:disease relationship that relates to the work of your Expert Panel?		Do you have any other existing or planned independent curation efforts that will potentially overlap with the scope of your ClinGen work? If so, please describe:	Please disclose any other relevant conflicts of interest (e.g. patents, intellectual property ownership, or paid consultancies related to any variants or genes associated with the work of your Expert Panel):
	Open-Ended Response	Response	Response	If yes, please list the genes:	Open-Ended Response	Open-Ended Response
2019-01-29 11:19:06	Valeria Novelli	Yes	Yes	SCN5A, PKP2, DSP, DSC2, DG2, CACNA1C, KCNH2		
2019-01-29 13:58:47	Marco Perez	No	No		No	No other relevant conflicts of interest
2018-12-19 6:27:16	Wojciech Zareba	No	Yes	long QT syndrome	No	
2018-09-13 13:10:20	James Ware	No	No		- I am part of the Transforming Genomic Medicine Initiative (TGMI), which is collaborating with ClinGen on harmonisation of terms for curation of genes, variants, mechanisms & inheritance modes (under the banner of the Gene Curation Coalition). - We have developed CardioClassifier (already published) - a decision support tool for variant interpretation. This has involved some curation to determine which genes should be included, which molecular mechanisms are relevant, and curation of variants. These are not being promoted as final, and our goal is to align with ClinGen outputs as the consensus curations come online.	I hold a patent related to technology to support variant interpretation. I have consultancy agreements with Third Rock Ventures & Myokardia (but not directly connected to the work of this EP).
2018-08-30 12:16:41	Ray Hershberger	No	No		no	none.
2018-08-29 11:54:17	Arthur Wilde	No	No		none	none
2018-06-17 13:20:30	m gollob	No	No		no	none
2018-06-15 7:52:24	Michael J. Ackerman, MD, PhD	No	Yes	CACNA1C, CAV3, SNTA1, AKAP9, CALM3, TRDN	Yes, we continue our research program regarding variant resolution and gene discovery	Consultant - Invitae
2018-06-15 0:21:40	E. Nannenber	No	No			none
2018-06-14 11:51:24	John Garcia		No		Invitae is constantly curating gene-disease relationships and interpreting variants. However, we use non-ACMG criteria	full-time employee of Invitae, which does diagnostic testing that includes these genes

					At Geisinger, we might need to curate the Long QT genes on our current "return" list, but we would likely wait to see what the ClinGen group publishes and then update our list based on the work of the ClinGen LQTS Gene Curation group. I will be sure to let Dr. Gollob know if we do any work in this regard.	
2018-06-14 11:35:19	Amy Sturm	No	No			None.
2018-05-14 1:04:19	Hennie Bikker	Yes	No		no	no disclosures
2018-05-13 9:15:21	Ahmad S. Amin	No	No		No.	Not applicable.
2018-05-12 3:35:20	Simona Amenta	No	No		No	
2018-05-11 12:08:29	Melanie Care	No	No		No	N/A
2018-05-08 23:08:25	Daniela	No	No		No	No
2018-04-27 2:46:16	Emanuela Abiusi	No	No		No	
2018-03-23 9:33:13	Harriet Feilotter	Yes	No			
2018-03-21 15:24:38	Arnon Adler	No	No			